0,643$
-1,10%
Echtzeit-Aktienkurs Karyopharm Therapeutics Inc.
Bid:
Ask:
Echtzeit-Chart der Karyopharm Therapeutics Inc. Aktie
Börsenkurse Karyopharm Therapeutics Inc.
| Echtzeit Euro | - | - | - | - | 0,619€ | -7,63% |
| gettex | - | - | - | - | 0,617€ | -0,96% |
| Lang & Schwarz | - | - | - | - | 0,620€ | -0,56% |
| Börse Stuttgart | - | - | - | - | 0,622€ | 2,74% |
| Tradegate | - | - | - | - | 0,616€ | -1,55% |
| Nasdaq | - | - | - | - | 0,644$ | -0,92% |
| Echtzeit USD | - | - | - | - | 0,643$ | -1,10% |
| Börse Frankfurt | - | - | - | - | 0,618€ | -0,19% |
| USA | - | - | - | - | 0,645$ | -0,75% |
Fundamentaldaten der Karyopharm Therapeutics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 146,03 Mio. | -142,78 Mio. | -143,10 Mio. | -1,25 | - | - | 0,51 |
| 2022 [USD] | 157,07 Mio. | -164,92 Mio. | -165,29 Mio. | -2,02 | - | - | 0,46 |
| 2021 [USD] | 209,82 Mio. | -123,82 Mio. | -124,09 Mio. | -1,65 | - | - | 0,23 |
| 2020 [USD] | 108,09 Mio. | -195,96 Mio. | -196,27 Mio. | -2,72 | - | - | 0,44 |
| 2019 [USD] | 40,89 Mio. | -199,55 Mio. | -199,59 Mio. | -3,22 | - | - | 1,03 |
| 2018 [USD] | 30,34 Mio. | -178,38 Mio. | -178,41 Mio. | -3,14 | - | - | 1,29 |
| 2017 [USD] | 1,61 Mio. | -128,92 Mio. | -128,98 Mio. | -2,81 | - | - | 19,84 |
| 2016 [USD] | 0,15 Mio. | -109,44 Mio. | -109,58 Mio. | -2,92 | - | - | 174,86 |
| 2015 [USD] | 0,25 Mio. | -118,18 Mio. | -118,18 Mio. | -3,32 | - | - | 92,23 |
| 2014 [USD] | 0,23 Mio. | -75,78 Mio. | -75,78 Mio. | -2,43 | - | - | 91,80 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Karyopharm Therapeutics Inc. Aktie
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological